G
Georg Kuhnert
Researcher at University of Cologne
Publications - 27
Citations - 1547
Georg Kuhnert is an academic researcher from University of Cologne. The author has contributed to research in topics: Procarbazine & Brentuximab vedotin. The author has an hindex of 15, co-authored 27 publications receiving 1109 citations. Previous affiliations of Georg Kuhnert include University of Hamburg.
Papers
More filters
Journal ArticleDOI
Comparison of [ 18 F]DCFPyL and [ 68 Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
Markus Dietlein,Carsten Kobe,Georg Kuhnert,Simone Stockter,Thomas Fischer,Klaus Schomäcker,Matthias Schmidt,Felix Dietlein,Boris D. Zlatopolskiy,Philipp Krapf,Raphael Richarz,Stephan Neubauer,Alexander Drzezga,Bernd Neumaier +13 more
TL;DR: [18F]DCFPyL PET/CT provided a high image quality and visualized small prostate lesions with excellent sensitivity and represents a highly promising alternative to [68Ga]Ga-PSMA-HBED-CC for PSMA-PET/CT imaging in relapsed prostate cancer.
Journal ArticleDOI
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Peter Borchmann,Helen Goergen,Carsten Kobe,Andreas Lohri,Richard Greil,Dennis A. Eichenauer,Josée M. Zijlstra,Jana Markova,Julia Meissner,Michaela Feuring-Buske,Andreas Hüttmann,Judith Dierlamm,Martin Soekler,Hans Joachim Beck,Wolfgang Willenbacher,Wolf-Dieter Ludwig,Thomas Pabst,Max S. Topp,Felicitas Hitz,Martin Bentz,Ulrich Keller,Dagmar Kühnhardt,Helmut Ostermann,Norbert Schmitz,Bernd Hertenstein,Walter E. Aulitzky,Georg Maschmeyer,Tom Vieler,Hans Theodor Eich,Christian Baues,Harald Stein,Michael Fuchs,Georg Kuhnert,Volker Diehl,Markus Dietlein,Andreas Engert +35 more
TL;DR: This open-label, randomised, parallel-group phase 3 trial investigated whether metabolic response determined by PET after two cycles of standard regimen eBEACOPP (PET-2) would allow adaption of treatment intensity, increasing it for PET-2-positive patients and reducing it forPET- 2-negative patients and showed non-inferiority in the 5-year progression-free survival estimates.
Journal ArticleDOI
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.
Achim Rothe,Stephanie Sasse,Max S. Topp,Dennis A. Eichenauer,Horst Hummel,Katrin S. Reiners,Markus Dietlein,Georg Kuhnert,Joerg Kessler,Carolin Buerkle,Miroslav Ravic,Stefan Knackmuss,Jens-Peter Marschner,Elke Pogge von Strandmann,Peter Borchmann,Andreas Engert +15 more
TL;DR: A phase 2 study is currently planned to optimize the dosing schedule in order to further improve the therapeutic efficacy of AFM13 and represent a well-tolerated, safe, and active targeted immunotherapy of Hodgkin lymphoma.
Journal ArticleDOI
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Michael Fuchs,Helen Goergen,Carsten Kobe,Georg Kuhnert,Andreas Lohri,Richard Greil,Stephanie Sasse,Max S. Topp,Erhardt Schäfer,Bernd Hertenstein,Martin Soekler,Martin Vogelhuber,Josee M. Zijlstra,Ulrich Keller,Stefan W. Krause,Martin Wilhelm,Georg Maschmeyer,Julia Thiemer,Ulrich Dührsen,Julia Meissner,Andreas Viardot,Hans Theodor Eich,Christian Baues,Volker Diehl,Andreas Rosenwald,Bastian von Tresckow,Markus Dietlein,Peter Borchmann,Andreas Engert +28 more
TL;DR: In early-stage favorable HL, a positive PET after two cycles ABVD indicates a high risk for treatment failure, particularly when a Deauville score of 4 is used as a cutoff for positivity in PET-2-positive patients.
Journal ArticleDOI
In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease.
Julian Dronse,Klaus Fliessbach,Klaus Fliessbach,Gérard N. Bischof,Boris von Reutern,Jennifer Faber,Jennifer Faber,Jochen Hammes,Georg Kuhnert,Bernd Neumaier,Oezguer A. Onur,Juraj Kukolja,Thilo van Eimeren,Frank Jessen,Gereon R. Fink,Thomas Klockgether,Thomas Klockgether,Alexander Drzezga +17 more
TL;DR: Tau PET imaging may serve as a valuable biomarker for the localization of neuronal injury in vivo and may help to validate atypical subtypes of Alzheimer's disease.